Astellas Extends Post-patent Lipitor Deal With Pfizer In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's patent cliff is more of a slope, allowing companies to squeeze profit from a post-patent drug despite government intervention to promote generics.
You may also be interested in...
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.